NASDAQ:SION Sionna Therapeutics Q4 2025 Earnings Report $5.51 -0.51 (-8.47%) Closing price 04:00 PM EasternExtended Trading$5.49 -0.02 (-0.29%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sionna Therapeutics EPS ResultsActual EPS-$0.46Consensus EPS -$0.61Beat/MissBeat by +$0.15One Year Ago EPSN/ASionna Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASionna Therapeutics Announcement DetailsQuarterQ4 2025Date3/2/2026TimeBefore Market OpensConference Call DateMonday, March 2, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Sionna Therapeutics Earnings HeadlinesRa Capital Management, L.P. Sells 3,448,811 Shares of Sionna Therapeutics (NASDAQ:SION) StockSeptember 23 at 4:09 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONSeptember 22 at 8:11 PM | globenewswire.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.September 23 at 1:00 AM | Decentralized Masters (Ad)Sionna Therapeutics, Inc.(NasdaqGM:SION) dropped from S&P Biotechnology Select Industry IndexSeptember 20 at 12:35 AM | marketscreener.comMLifeSci Capital Sticks to Its Hold Rating for Sionna Therapeutics, Inc. (SION)September 20 at 2:23 PM | theglobeandmail.comSionna Therapeutics, Inc. (NASDAQ:SION) Receives $42.22 Consensus Target Price from AnalystsSeptember 18, 2026 | americanbankingnews.comSee More Sionna Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sionna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sionna Therapeutics and other key companies, straight to your email. Email Address About Sionna TherapeuticsSionna Therapeutics (NASDAQ:SION) is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disease that affects the lungs and other organs. The company is developing small-molecule therapies designed to address defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is responsible for transporting salt and fluids across cell membranes. Sionna’s research is centered on nucleotide-binding domain 1 (NBD1) correctors. These investigational medicines are intended to stabilize and improve the function of defective CFTR proteins, including proteins affected by the common F508del mutation. The company’s approach is designed to potentially form part of combination therapies that target multiple stages of CFTR production, processing and activity. Sionna’s pipeline includes preclinical and clinical-stage programs evaluating the safety, tolerability and pharmacological activity of its CFTR modulators. The company’s goal is to develop oral treatments that may benefit a broad population of people with cystic fibrosis, including patients who have limited treatment options because of the specific mutations they carry.View Sionna Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
